[go: up one dir, main page]

CU22700A1 - Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso - Google Patents

Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso

Info

Publication number
CU22700A1
CU22700A1 CU1997106A CU1997106A CU22700A1 CU 22700 A1 CU22700 A1 CU 22700A1 CU 1997106 A CU1997106 A CU 1997106A CU 1997106 A CU1997106 A CU 1997106A CU 22700 A1 CU22700 A1 CU 22700A1
Authority
CU
Cuba
Prior art keywords
peptide
pharmaceutical formulation
formulation containing
hep
lalf
Prior art date
Application number
CU1997106A
Other languages
English (en)
Inventor
Rosainz Manuel De Jesus Arana
Vallespi Maribel Guerra
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU1997106A priority Critical patent/CU22700A1/es
Priority to US09/160,309 priority patent/US6191114B1/en
Priority to PT98203293T priority patent/PT905141E/pt
Priority to AT98203293T priority patent/ATE268784T1/de
Priority to DE69824358T priority patent/DE69824358T2/de
Priority to EP98203293A priority patent/EP0905141B1/en
Priority to ES98203293T priority patent/ES2223105T3/es
Priority to DK98203293T priority patent/DK0905141T3/da
Priority to SI9830682T priority patent/SI0905141T1/xx
Priority to CN98124538A priority patent/CN1218057A/zh
Priority to US09/691,500 priority patent/US6632793B1/en
Publication of CU22700A1 publication Critical patent/CU22700A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Insects & Arthropods (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Formulació farmacéutica con ación antivral ejercida por un péptido de la proteína Factor anti-LPS de Limulus y su nuevo efecto inmunológico como antiviral. estos efectos inmunlógicos están dados por: (1) conferir actividad antiviral en líneas celulares; (2) el sobrenadante proveniente de la incubación de monocitos humanos con el péptido es capaz de proteger a las células de una infección viral a través de la liberación de interferón, (3) regulación de la respuesta inmune in vitro e in vivo. La presente formulación puede ser usada en el tratamiento profiláctico o terapéutico de humanos y animales para de modular la respuesta inmune del huésped, favoreciendo la protección contra enfermedades infecciosas virales, sin estimular la producción de TNF-alfa que pueden causar efectos no deseados como fiebre e inflamación.
CU1997106A 1997-09-29 1997-09-29 Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso CU22700A1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CU1997106A CU22700A1 (es) 1997-09-29 1997-09-29 Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso
US09/160,309 US6191114B1 (en) 1997-09-29 1998-09-25 Immunological activity for a peptide of the limulus anti-LPS factor
PT98203293T PT905141E (pt) 1997-09-29 1998-09-29 Fragmento peptidico do factor anti-lps de limulus ("lalf") com accao antiviral
AT98203293T ATE268784T1 (de) 1997-09-29 1998-09-29 Peptidfragment von lalf mit antiviraler wirkung
DE69824358T DE69824358T2 (de) 1997-09-29 1998-09-29 Peptidfragment von LALF mit antiviraler Wirkung
EP98203293A EP0905141B1 (en) 1997-09-29 1998-09-29 Peptide fragment of the limulus anti-LPS factor (LALF) having antiviral action
ES98203293T ES2223105T3 (es) 1997-09-29 1998-09-29 Fragmento peptido del factor anti-lps de limulo (lalf) que tiene accion antivirica.
DK98203293T DK0905141T3 (da) 1997-09-29 1998-09-29 Peptidfragment af Limulus anti-LPS faktor (LALF) med antiviral virkning
SI9830682T SI0905141T1 (en) 1997-09-29 1998-09-29 Peptide fragment of the limulus anti-LPS factor (LALF) having antiviral action
CN98124538A CN1218057A (zh) 1997-09-29 1998-09-29 鲎属抗lps因子的肽的新免疫学活性
US09/691,500 US6632793B1 (en) 1997-09-29 2000-10-18 Immunological activity for a peptide of the limulus anti-LPS factor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1997106A CU22700A1 (es) 1997-09-29 1997-09-29 Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso

Publications (1)

Publication Number Publication Date
CU22700A1 true CU22700A1 (es) 2001-07-31

Family

ID=5459370

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1997106A CU22700A1 (es) 1997-09-29 1997-09-29 Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso

Country Status (10)

Country Link
US (2) US6191114B1 (es)
EP (1) EP0905141B1 (es)
CN (1) CN1218057A (es)
AT (1) ATE268784T1 (es)
CU (1) CU22700A1 (es)
DE (1) DE69824358T2 (es)
DK (1) DK0905141T3 (es)
ES (1) ES2223105T3 (es)
PT (1) PT905141E (es)
SI (1) SI0905141T1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040199099A1 (en) * 1998-07-10 2004-10-07 Matson James R Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
US6592869B2 (en) 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
HUP0202537A3 (en) 1999-08-24 2004-05-28 Teva Pharma A vaccine composition and method of using the same
US7291122B2 (en) * 2000-03-24 2007-11-06 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US6787040B2 (en) * 2000-05-16 2004-09-07 Immunocept, L.L.C. Method and system for colloid exchange therapy
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
CA2495459C (en) * 2002-08-13 2009-10-27 Arbios Technologies Inc. Selective plasma exchange therapy
CU23389B6 (es) * 2005-12-29 2009-07-16 Ct Ingenieria Genetica Biotech Combinación farmacéutica citoprotectora, útil en la prevención y tratamiento del síndrome de respuesta inflamatoria sistémica
CU23582A1 (es) * 2006-02-24 2010-10-30 Ct Ingenieria Genetica Biotech Péptidos con capacidad anti-tumoral e inmunomoduladora
EP2108372A1 (en) * 2008-04-09 2009-10-14 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Novel antimicrobial peptides
CN113563427B (zh) * 2021-06-02 2022-02-01 北京师范大学珠海校区 抗菌短肽lbd-s及其应用和药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020715A1 (en) 1991-05-16 1992-11-26 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
JPH08503490A (ja) * 1993-08-18 1996-04-16 モルフォシス・ゲゼルシャフト・フュア・プロタインオプティミールング・ミット・ベシュレンクテル・ハフツング リポ多糖結合性および中和能のあるペプチド
US5780429A (en) * 1995-12-22 1998-07-14 Marine Biological Laboratory Anti-LPS factor from horseshoe crabs and methods of use

Also Published As

Publication number Publication date
PT905141E (pt) 2004-10-29
EP0905141A1 (en) 1999-03-31
DK0905141T3 (da) 2004-10-25
US6191114B1 (en) 2001-02-20
SI0905141T1 (en) 2004-12-31
ATE268784T1 (de) 2004-06-15
DE69824358D1 (de) 2004-07-15
ES2223105T3 (es) 2005-02-16
US6632793B1 (en) 2003-10-14
CN1218057A (zh) 1999-06-02
EP0905141B1 (en) 2004-06-09
DE69824358T2 (de) 2005-06-09

Similar Documents

Publication Publication Date Title
CU22700A1 (es) Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso
DE69425661D1 (de) IMIDAZO [4,5-c]PYRIDIN-4-AMINE
DE69331324D1 (de) Neue glukan-zubereitung
PA8481501A1 (es) 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas
ES2139574T3 (es) Nuevos gases propulsores y su uso en preparaciones medicas.
MX7531E (es) Proceso biotecnologico para alterar la proliferacion y/o el desarrollo de cultivos tisulares
MX9203294A (es) Factor de estimulacion de aniquilador natural.
DE3582973D1 (de) Neues derivat des humangammainterferon-polypeptids.
NO983372L (no) Modulering av TH1/TH2 cytokinekspresjon av Ribavirin og Ribavirinanaloger i aktiverte T-lymfocytter
SE8700203L (sv) Pyroglutamidderivat
IT1116848B (it) Perfezionamento nelle composizioni anti-virali particolarmente per il trattamento di infezioni rinovirali e procedimento per la loro preparazione
GT198301619A (es) Interferon inmune humano homogeneo y procedimiento para el mismo.
FI931204A0 (fi) Nya, saosom lipooxigenasinhibitorer verkande aminobensosultamderivat
ITBZ920053A1 (it) Dispositivo per la rotazione di pezzi da lavorare giacenti di piatto e fatti avanzare
IT8868117A0 (it) Solfonammidi di benzilidene canfora derivanti da amminoacidi e loro impiego in cosmesi particolarmente come filtri solari
NO864514D0 (no) Fremgangsmaate for fremstilling av thiazoloner.
FI821035A7 (fi) Imidatso/1,2-a/pyrimidiinijohdannaiset, niiden valmistus ja käyttö tautien hoidossa.
ITRM910435A1 (it) Preparato farmaceutico da utilizzare quale trattamento coadiuvante della dermatite seborroica anche in soggetti hiv positivi
EP0475374A3 (en) Use of branched chain amino acids to effect diaphragm contractility and fatigue
AU9034291A (en) Derivates of the human parathormone fragment (1-37) in the amide or ethylamide form as active substance
DE69429521D1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
ES2018370A6 (es) Un procedimiento para la preparacion de un gel de poliacrilato sodico.
ES2063056T3 (es) Esteres poliaromaticos de antibioticos macrolidicos y lincosamidicos, su procedimiento de preparacion y composiciones farmaceuticas y cosmeticas que los contienen.
IT1164027B (it) Procedimento per la preparazione di cloridrati di amminoacidi e bicloridrati di diamminoacidi
ES2063765T3 (es) Esteres cicloalifaticos insaturados de antibioticos macrolidicos y lincosamidicos, su procedimiento de preparacion y composiciones farmaceuticas y cosmeticas que los contienen.